Skip to Content
Merck
All Photos(1)

Key Documents

SC1002

Sigma-Aldrich

Anti-Sox2 Mouse mAb (245610)

lyophilized, clone 245610, Calbiochem®

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified antibody

antibody product type

primary antibodies

clone

245610, monoclonal

form

lyophilized

species reactivity

human, mouse

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze

isotype

IgG2a

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

mouse ... Sox2(20674)

General description

Protein G purified mouse monoclonal antibody derived by immunizing mice with the specified immunogen and fusing splenocytes with mouse myeloma cells. Recognizes the ~34 kDa Sox2 protein.
Recognizes the ~34 kDa Sox2 protein in NTERA-2 cells.
This Anti-Sox2 Mouse mAb (245610) is validated for use in Immunoblotting, Immunocytochemistry, Flow Cytometry for the detection of Sox2.

Immunogen

Human
a recombinant protein consisting of amino acids 135-317 of human Sox2, expressed in E. coli

Application

Immunoblotting (1-2 µg/ml)

Immunocytochemistry (10 µg/ml; see comments)

Flow Cytometry (see comments)

Warning

Toxicity: Standard Handling (A)

Physical form

Lyophilized from 0.2 µm-filter sterilized PBS, 5% trehalose.

Reconstitution

Reconstitute with 200 µl sterile PBS for a final stock concentration of 500 µg/ml. Following reconstitution, aliquot and freeze (-20°C or -70°C) for long-term storage. Avoid freeze/thaw cycles of solutions. Thawed aliquots are stable for up to 1 month at 4°C.

Analysis Note

Positive Control
NTERA-2 cells

Other Notes

Avilion, A.A., et al. 2003.Genes Dev.17, 126.
Graham, V., et al. 2003.Neuron39, 749.
Stevanovic, M. 2003.Mol. Biol. Rep.30, 127.
Kishi, M., et al. 2000.Development127, 791.
Uwanogho, D., et al. 1995.Mech. Dev.49, 23.
Yuan, H., et al. 1995.Genes Dev.9, 2635.
For immunocytochemistry, cells should be fixed in PBS containing 4% paraformaldehyde for 20 min, followed by blocking in PBS/10% normal donkey serum/1% BSA/0.1% Triton X-100 detergent for 45 min and staining overnight at 4°C with appropriately diluted primary antibody. For immunoblotting, the best results may be obtained using whole cell or nuclear extracts; Sox2 may be difficult to detect in cytoplasmic extracts. The detection limit for recombinant Sox2 is ~5 ng/lane under reducing and non-reducing conditions. For intracellular staining by flow cytometry, fix cells in 4% paraformaldehyde and permeabilize with 0.1% saponin. Following fixation and permeabilization, dilute the antibody to 50 µg/ml and add 10 µl diluted antibody to 1-2.5 x 105 cells in a total volume of ≤200 µl. Following incubation with appropriate detection antibody, the cells should be washed a final time with 0.1% saponin prior to analysis. Antibody should be titrated for optimal results in individual systems.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Triton is a trademark of The Dow Chemical Company or an affiliated company of Dow

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

11 - Combustible Solids

WGK

WGK 1


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mohammad Zandi et al.
International journal of fertility & sterility, 9(3), 361-370 (2015-12-09)
This research studies the effects of activation and inhibition of Wnt3A signaling pathway in buffalo (Bubalus bubalis) embryonic stem (ES) cell-like cells. To carry on this experimental study, the effects of activation and inhibition of Wnt3A signaling in buffalo ES
Ana Belén Alvarez-Palomo et al.
Stem cells (Dayton, Ohio), 39(7), 866-881 (2021-02-24)
A key challenge for clinical application of induced pluripotent stem cells (iPSC) to accurately model and treat human pathologies depends on developing a method to generate genetically stable cells to reduce long-term risks of cell transplant therapy. Here, we hypothesized
Huahu Ye et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 50(4), 1318-1331 (2018-10-26)
Induced pluripotent stem cells (iPSCs) hold great promise for regenerative medicine, disease modeling, and drug development. Thus, generation of non-integration and feeder-free iPSCs is highly desirable for clinical applications. Peripheral blood mononuclear cells (PBMCs) are an attractive resource for cell
Ran Zhou et al.
Molecular reproduction and development, 86(11), 1671-1681 (2019-08-21)
Incomplete transgene-silencing remains a challenge in the generation of induced pluripotent stem cells (iPSC) in felids-a critical family in biomedical and biodiversity conservation science. In this study doxycycline-inducible transgenes (NANOG, POU5F1, SOX2, KLF4, and cMYC) were used to reprogram cat
Mohammad Zandi et al.
Cell journal, 17(2), 264-273 (2015-07-23)
In order to retain an undifferentiated pluripotent state, embryonic stem (ES) cells have to be cultured on feeder cell layers. However, use of feeder layers limits stem cell research, since experimental data may result from a combined ES cell and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service